HyOrc Corp has secured $70,200 in convertible notes through separate agreements with Jefferson Street Capital LLC and Lambda Ventures LLC. The notes carry a 12% interest charge and can be converted into common stock at a price equal to 77% of the lowest traded price. This funding gives HyOrc Corp access to up to $7.5M in Equity funding through an equity purchase agreement with Lambda.

Key Highlights

  • HyOrc Corp secures $70,200 in convertible notes via agreements with Jefferson Street Capital LLC and Lambda Ventures LLC.
  • The notes bear a 12% interest charge and may be exchanged for common shares at a conversion price set at 77% of the lowest recent trading price.
  • Through a separate equity purchase arrangement with Lambda, HyOrc Corp can obtain up to $7.5M in additional equity financing.

New Funding Arrangements

HyOrc Corp has signed securities purchase contracts with Jefferson Street Capital LLC and Lambda Ventures LLC, together providing $70,200 in convertible notes. Each note was sold for $32,500 and carries an original issue discount of $2,600. This infusion supplies the capital necessary for the company’s operational objectives and reflects a cost‑effective financing structure for shareholders.

Terms of the Convertible Notes

The convertible notes include a one‑time interest charge of 12% applied to the principal amount and are scheduled to mature twelve months after issuance. Six months after the issue date, noteholders may elect to convert any portion of the outstanding principal and accrued interest into HyOrc Corp’s common stock. The conversion price is calculated at 77% of the lowest price at which the company’s shares traded on the principal market during the fifteen days preceding the conversion event.

In connection with the note issuances, HyOrc Corp agreed to allocate 125,000 restricted common shares to each investor, resulting in a total of 250,000 commitment shares.

Equity Purchase Agreement

In addition to the notes, HyOrc Corp entered into an equity purchase agreement with Lambda Ventures LLC. Under this agreement, Lambda has the option to purchase shares of HyOrc Corp up to a total aggregate amount of $7,500,000 during the commitment period. The purchase price for any shares sold under a put provision follows a pricing formula outlined in the agreement, which is generally anchored to 80% of the prevailing market price.

This arrangement affords HyOrc Corp the flexibility to raise significant equity capital if needed, supporting strategic initiatives and growth opportunities.

Sector Context and Outlook

Convertible notes are a common financing tool for companies listed on over‑the‑counter exchanges, offering investors downside protection through a fixed interest component while preserving upside potential via conversion features. For a biotech‑focused firm like HyOrc Corp, access to both debt‑like capital and a sizable equity line can be instrumental in advancing research, clinical trials, and commercial rollout.

What to Watch Next

Stakeholders should monitor the upcoming quarterly filing, which will detail how the newly secured resources are allocated across research, development, and operational activities. The effectiveness of HyOrc Corp’s execution against its Business Plan will be a key indicator of future performance and Shareholder value.

Analysis based on the Form 8-K filed 10 August 2026; figures verified against the filing.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making Investment decisions.